GYS1

Across TCGA pan-cancer cohorts, GYS1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GYS1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GYS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GYS1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where GYS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.292	0.525	.002	33	view →
LSCC	OS	Median	III,IV	0.905	0.560	.027	10	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	9	view →
GBM	DFS	Quartile	All	0.582	0.804	.033	3	view →
HNSC	DFS	Quartile	All	0.915	1.000	.025	3	view →
LUAD	OS	Quartile	III,IV	0.444	0.879	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GYS1–PDAC (DFS)

Open the PDAC breakdown →